PD-L1 and alternative immune checkpoints AICs in non-small cell lung cancer NSCLC Insights into the tumor immune microenvironment TIME and immunotherapy IO outcomes | Caris Life Sciences
Home / Research / Publications / PD-L1 and alternative immune checkpoints AICs in non-small cell lung cancer NSCLC Insights into the tumor immune microenvironment TIME and immunotherapy IO outcomes

Publications

PD-L1 and alternative immune checkpoints AICs in non-small cell lung cancer NSCLC Insights into the tumor immune microenvironment TIME and immunotherapy IO outcomes

Background:

  • We previously showed that HHLA2 is expressed in ~2/3NSCLC and associated with EGFR mutation status (1), and that the majority of PD-L1 neg NSLCC express B7x and HHLA2 (2)
  • We sought to explore patterns of PD-L1 and AICs within the TIME and impact on IO outcomes
Read the Full Manuscript Download Publication
Learn More
Name(Required)